Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin

Diabetes, Obesity and Metabolism

Volumn 18, Issue 2, 2016, Pages 152-158

  Freemantle, N ^a   Danchin, N ^b   Calvi Gries, F ^c   Vincent, M ^d   Home, P D ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Atlanstat   (France)

^d SANOFI   (France)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cardiovascular risk; CREDIT; Glycaemic control; Hypoglycaemia; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DISEASE SEVERITY; EUROPE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORTH AMERICA; PROSPECTIVE STUDY; RISK FACTOR; BLOOD; CANADA; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; HYPERGLYCEMIA; JAPAN; LONGITUDINAL STUDY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; CANADA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; EUROPE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84956874593     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12598     Document Type: Article

References (25)

1. Dormandy JA, Charbonnel B, Eckland DJ etal. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
2. Duckworth W, Abraira C, Moritz T etal. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
3. Gerstein HC, Miller ME, Byington RP etal. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
4. Patel A, MacMahon S, Chalmers J etal. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
5. Home P, Naggar NE, Khamseh M etal. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract 2011; 94: 352-363.
6. Riddle MC, Ambrosius WT, Brillon DJ etal. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33: 983-990.
7. Siraj ES, Rubin DJ, Miller ME etal. The relationship between insulin exposure and cardiovascular mortality in the ACCORD trial. Diabetes 2013; 62 (Suppl. 1): A98.
8. Bonds DE, Miller ME, Bergenstal RM etal. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: b4909.
9. Zoungas S, Patel A, Chalmers J etal. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-1418.
10. Balkau B, Home PD, Vincent M, Marre M, Freemantle N. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care 2014; 37: 2108-2113.
11. Freemantle N, Balkau B, Home PD. A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes. Diabetes Obes Metab 2013; 15: 1120-1127.
12. Freemantle N, Balkau B, Danchin N etal. Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. Diabetes Obes Metab 2012; 14: 901-909.
13. Home PD, Dain MP, Freemantle N etal. Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. Diabetes Res Clin Pract 2015; 108: 350-359.
14. Gerstein HC, Bosch J, Dagenais GR etal. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328.
15. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003; 289: 2554-2559.
16. Collett D. Modelling Survival Data in Medical Research. London: Chapman & Hall/CRC, 1994.
17. Stratton IM, Adler AI, Neil HA etal. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
18. Turnbull FM, Abraira C, Anderson RJ etal. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
19. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
20. Gerstein HC, Miller ME, Ismail-Beigi F etal. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet 2014; 384: 1936-1941.
21. Hayward RA, Reaven PD, Wiitala WL etal. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 372: 2197-2206.
22. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
23. Ray KK, Seshasai SR, Wijesuriya S etal. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
24. Mellbin LG, Ryden L, Riddle MC etal. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013; 34: 3137-3144.
25. Del Prato S, Blonde L, Martinez L etal. The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial. Diabet Med 2008; 25: 662-670.